

**WEINBERG et al**  
**Serial No. 08/753,851**

Amend the claims as follows:

10. (Amended) The method according to claim 8 wherein said agent is a CD44 oligopeptide selected from the group consisting of CD44-1 (SEQ ID NO:1), CD44-2 (SEQ ID NO:2), CD44-3 (SEQ ID NO:3), CD44-4 (SEQ ID NO:4), CD44-5 (SEQ ID NO:5), CD44-6 (SEQ ID NO:6), CD44-6a (SEQ ID NO:7), CD44-7 (SEQ ID NO:8), CD44-8 (SEQ ID NOS: 9, 10 AND 11), CD44-9 (SEQ ID NO:12), CD44-10 (SEQ ID NO:13), CD44-11 (SEQ ID NO:14), CD44-12 (SEQ ID NO:15), and CD44-13 (SEQ ID NO:16).

**REMARKS**

Reconsideration of this application and entry of the foregoing amendments are respectfully requested.

Claim 10 has been amended to define the invention with additional clarity. Claims 21 and 22 have been canceled without prejudice to the filing of a continuation application covering same. That the claims have been revised/canceled should not be construed as an indication that Applicants agree with any view expressed by the Examiner. Rather, the claims have been revised/canceled merely to advance prosecution.